CA2790219C - Treatment or prevention of infection - Google Patents

Treatment or prevention of infection Download PDF

Info

Publication number
CA2790219C
CA2790219C CA2790219A CA2790219A CA2790219C CA 2790219 C CA2790219 C CA 2790219C CA 2790219 A CA2790219 A CA 2790219A CA 2790219 A CA2790219 A CA 2790219A CA 2790219 C CA2790219 C CA 2790219C
Authority
CA
Canada
Prior art keywords
protein
subject
peptide
immunogen
gingivalis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2790219A
Other languages
English (en)
French (fr)
Other versions
CA2790219A1 (en
Inventor
Eric Charles Reynolds
Original Assignee
Oral Health Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010900846A external-priority patent/AU2010900846A0/en
Application filed by Oral Health Australia Pty Ltd filed Critical Oral Health Australia Pty Ltd
Publication of CA2790219A1 publication Critical patent/CA2790219A1/en
Application granted granted Critical
Publication of CA2790219C publication Critical patent/CA2790219C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2790219A 2010-02-26 2011-02-25 Treatment or prevention of infection Active CA2790219C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010900846 2010-02-26
AU2010900846A AU2010900846A0 (en) 2010-02-26 Treatment or prevention of infection
PCT/AU2011/000206 WO2011103633A1 (en) 2010-02-26 2011-02-25 Treatment or prevention of infection

Publications (2)

Publication Number Publication Date
CA2790219A1 CA2790219A1 (en) 2011-09-01
CA2790219C true CA2790219C (en) 2020-06-30

Family

ID=44506081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790219A Active CA2790219C (en) 2010-02-26 2011-02-25 Treatment or prevention of infection

Country Status (17)

Country Link
US (1) US9125853B2 (enExample)
EP (2) EP3260135A1 (enExample)
JP (1) JP5977677B2 (enExample)
KR (2) KR20170109685A (enExample)
CN (2) CN102883744A (enExample)
AU (1) AU2011220335B2 (enExample)
BR (1) BR112012021383A2 (enExample)
CA (1) CA2790219C (enExample)
HK (1) HK1248535A1 (enExample)
MX (1) MX342832B (enExample)
MY (1) MY162557A (enExample)
NZ (1) NZ601890A (enExample)
RU (1) RU2617399C2 (enExample)
SG (2) SG183376A1 (enExample)
TW (1) TWI583392B (enExample)
WO (1) WO2011103633A1 (enExample)
ZA (1) ZA201206204B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP2328914B1 (en) * 2008-08-29 2017-05-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of p.gingivalis infection
WO2010144968A1 (en) * 2009-06-19 2010-12-23 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides
WO2016061264A1 (en) * 2014-10-14 2016-04-21 The Forsyth Institute Conjugates for delivery to mitochondria
KR101587113B1 (ko) * 2014-10-29 2016-01-20 경북대학교 산학협력단 치주염 유발 장알균(Enterococcus faecalis)을 특이적으로 사멸시키는 신규한 박테리오파지
EP3389704B1 (en) * 2015-12-15 2022-01-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Vaccination against diabetes, obesity and complications thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CA3133097A1 (en) 2019-03-13 2020-09-17 The University Of Melbourne Compositions and methods for promoting mineralization

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA2128711C (en) 1992-01-30 2005-01-11 Terence K. Brunck Trypsin inhibitors
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
AUPP893999A0 (en) 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
AUPQ485999A0 (en) 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
GB2370838A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex
JP2005537245A (ja) 2002-06-26 2005-12-08 エントレメッド インコーポレイテッド タンパク質活性化レセプターのアンタゴニストを含む組成物および方法
US20070036734A1 (en) 2003-03-17 2007-02-15 Kirin Beer Kabushiki Kaisha Therapeutic agent for periodontal disease
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
ATE495189T1 (de) * 2003-08-15 2011-01-15 Univ Florida Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
GB0411150D0 (en) * 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
CA2576971A1 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
NZ554331A (en) 2004-09-23 2009-04-30 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
US7888482B2 (en) 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
CA2652957A1 (en) 2006-06-27 2008-01-03 Oral Health Australia Pty Ltd. Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease
EP2638905B1 (en) 2007-07-12 2019-01-16 Oral Health Australia Pty Ltd Biofilm treatment
RU2366378C1 (ru) * 2008-04-07 2009-09-10 Сергей Владимирович Сирак Способ костной пластики при непосредственной дентальной имплантации
MX2012001495A (es) * 2009-08-02 2012-08-03 Sanofi Pasteur Ltd Polipeptidos de porphyromonas gingivalis.

Also Published As

Publication number Publication date
MY162557A (en) 2017-06-15
US9125853B2 (en) 2015-09-08
AU2011220335A1 (en) 2012-09-06
HK1248535A1 (en) 2018-10-19
WO2011103633A1 (en) 2011-09-01
MX2012009730A (es) 2013-02-07
EP2538970A4 (en) 2013-12-18
TWI583392B (zh) 2017-05-21
RU2617399C2 (ru) 2017-04-24
KR20170109685A (ko) 2017-09-29
KR20130036185A (ko) 2013-04-11
JP2013520448A (ja) 2013-06-06
CN104689308B (zh) 2020-10-20
BR112012021383A2 (pt) 2017-07-25
JP5977677B2 (ja) 2016-08-24
TW201138813A (en) 2011-11-16
RU2012136724A (ru) 2014-04-10
SG10201500976XA (en) 2015-04-29
CN102883744A (zh) 2013-01-16
EP3260135A1 (en) 2017-12-27
AU2011220335B2 (en) 2015-04-02
SG183376A1 (en) 2012-09-27
CN104689308A (zh) 2015-06-10
MX342832B (es) 2016-10-14
ZA201206204B (en) 2013-05-29
US20130129768A1 (en) 2013-05-23
EP2538970A1 (en) 2013-01-02
CA2790219A1 (en) 2011-09-01
NZ601890A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
US11572391B2 (en) Antibodies for prevention, treatment and diagnosis of P. gingivalis infection
AU2011220335B2 (en) Treatment or prevention of infection
AU2011220335A2 (en) Treatment or prevention of infection
US20120294881A1 (en) Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
HK1157357B (en) Prevention, treatment and diagnosis of p.gingivalis infection
HK1157357A (en) Prevention, treatment and diagnosis of p.gingivalis infection
AU2013203249A1 (en) Prevention, treatment and diagnosis of P.gingivalis infection

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160224

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260408